Preliminary positive results announced from second phase II study of Lyme disease vaccine candidate VLA15

Lyme disease is caused by the Borrelia bacteria transmitted to humans by infected ticks. The vaccine candidate targets the outer surface protein A (OspA) of the bacteria. Seroconversion rates after completion of the primary vaccinations ranged from 93.8% to 98.8%.

PharmaTimes